Noveltreat 2.4mg Injection

Q1: What is Noveltreat 2.4mg used for?

Noveltreat 2.4mg is the maximum maintenance dose of injectable semaglutide from Knoll Pharma, used for long-term chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Q2: How does Noveltreat 2.4mg compare to Wegovy 2.4mg?

Both deliver the same dose of semaglutide (2.4mg) once weekly. Noveltreat is an Indian-manufactured generic providing equivalent clinical effect — approximately 15% body weight reduction over 68 weeks — at a fraction of Wegovy's price.

Q3: What kind of weight loss can I expect on Noveltreat 2.4mg?

Clinical data on semaglutide 2.4mg (STEP-1 trial) shows an average 15% body weight reduction over 68 weeks with lifestyle intervention. Approximately one-third of patients achieve over 20% body weight reduction at the maximum dose.

Q4: Is Noveltreat 2.4mg a long-term treatment?

Yes. Semaglutide 2.4mg requires indefinite maintenance to sustain weight loss. Stopping the medication leads to return of appetite and weight regain in the majority of patients within 1–2 years.

Q5: Can Noveltreat 2.4mg prevent type 2 diabetes?

High-dose semaglutide studies have shown over 90% reduction in progression from prediabetes to type 2 diabetes. Noveltreat 2.4mg, like its innovator equivalent, is expected to provide the same preventive benefit in high-risk individuals.

Q6: What makes Noveltreat 2.4mg affordable compared to Wegovy?

Noveltreat is manufactured in India with significantly lower production and regulatory costs. Indian pricing regulations and the generic manufacturing model allow Knoll Pharma to offer the identical dose at 70–80% lower cost than the global originator brand.

Q7: Does Noveltreat 2.4mg cause muscle loss?

All significant weight loss involves some lean mass reduction. Resistance exercise and adequate dietary protein (1.2–1.5 g/kg ideal body weight) substantially reduce the proportion of weight lost from muscle. Evidence suggests semaglutide preserves lean mass proportionally better than very low-calorie diets.

Q8: How do I transition from lower Noveltreat doses to 2.4mg?

The standard escalation is 0.25mg for 4 weeks, then 0.5mg for 4 weeks, then 1mg for 4 weeks, then 1.7mg for 4 weeks, then 2.4mg for long-term maintenance — a 16-week titration schedule designed to optimise tolerability.

Q9: What happens if I accidentally skip two or more consecutive weekly Noveltreat injections?

If you miss two or more consecutive weeks, your body loses much of its adapted tolerance to semaglutide. Restarting at 2.4mg may cause severe GI side effects. Contact your prescriber, who will likely advise restarting at a lower dose and re-escalating.

Q10: Can Noveltreat 2.4mg be used in patients with chronic kidney disease?

Mild to moderate CKD does not preclude semaglutide use; no dose adjustment is required. Severe CKD (eGFR < 15) warrants caution. Adequate hydration is especially important in CKD patients on semaglutide due to dehydration risk from GI side effects.